Navigation Links
ULURU Inc. Announces Closing Of $440,000 Private Placement
Date:3/15/2013

ADDISON, Texas, March 15, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR),a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced the completion of a definitive agreement to sell an aggregate of 1,100,000 shares of its common stock at a price per share of $0.40 pursuant to a previously announced private placement to management, resulting in gross proceeds of $440,000.  Participating in the private placement were Kerry P. Gray , the Company's Chairman, President and Chief Executive Officer and Terrance K. Wallberg , the Company's Vice President and Chief Financial Officer. 

The officers also received warrants to purchase up to an aggregate of 660,000 shares of ULURU Inc.'s common stock.  The warrants have a fixed exercise price of $0.60 per share and are exercisable at any time on or after 180 days from the closing date and for a period of five years from the date of closing.

Under the terms of the definitive agreement, the purchase and sale of the shares and warrants will take place at four closings over the next twelve months, with $88,000 being funded upon signing of the definitive agreement. 

The shares of common stock to be issued and any shares issued resulting from the exercise of warrants have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements.

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the anticipated closing of the transaction and the Company's products. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's lack of profitability, the need for additional capital to operate its business, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Third Quarter 2012 Financial Results
2. ULURU Inc. Announces The First Shipment Of Veterinary Product
3. ULURU Inc. Announces First Order Of Altrazeal For European Launch
4. ULURU Inc. Reports Second Quarter 2012 Financial Results
5. ULURU Inc. Announces Completion Of $2.2mil Convertible Debt Offering
6. Cardica Announces Proposed Public Offering of Common Stock
7. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
8. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
9. Simbionix Announces License Agreement for Surgical Videos
10. BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
11. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are used to treat ... if one isn’t accessible in certain locations, the risk of death can be ... with this idea," said an inventor from Ridgecrest, Calif. , The MOBILE AUTOMATED ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... SABRE Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from ... in Educational Leadership and Administration at St. Thomas University in Miami, Florida, was ...
(Date:9/22/2017)... ... September 22, 2017 , ... First Choice ... celebrating the one year anniversary of its Houston-Fallbrook facility. , “We are ... Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has been a ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... and more products at customers’ doorstep. According to Smart Mart, customers can now ... stated to offer wearable, and customers can find clothing at discounted prices. Apart ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for Medical ... p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing ... The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning ...
Breaking Medicine News(10 mins):